News

NLS Magazine No 01 2024 – Out now!

26 February 2024 | 5:47 am
NLS Magazine No 01 2024 – Out now!
News

Kancera resolves on a right issue and enters license agreement

26 February 2024 | 4:41 am
Kancera resolves on a right issue and enters license agreement
The board of directors of Kancera has resolved on a new share issue with preferential rights for the company’s existing shareholders of approximately SEK 121.9 million. The objective of the Rights Issue is to secure resources to advance the company’s development program, consisting of the candidate drugs KAND567 and KAND145, to start of new clinical […]
News

She is the winner of Arthur D. Little Nordic Life Science Award

22 February 2024 | 8:07 am
Gunilla Osswald
Gunilla Osswald, CEO, BioArctic, has been awarded The Arthur D. Little Nordic Life Science Award 2024. The award is given to people in the Nordics who demonstrate exceptional leadership within the life science industry. Exceptional leadership The jury states that Gunilla Osswald receives the award for exceptional leadership and particularly highlights her ability to create […]
News

New report shows hundreds of Nordic clinical trials remain unpublished

20 February 2024 | 2:25 pm
New report shows hundreds of Nordic clinical trials remain unpublished
A report jointly published by the AllTrials campaign, Cochrane Denmark, Cochrane Norway, Cochrane Sweden, the Dam Foundation, Melanomföreningen, and TranspariMED, shows that 475 clinical trials involving 83,903 patients completed during 2016-19 in Denmark, Iceland, Finland, Norway and Sweden, have never made their results public in any form. This accounted for 22% of all clinical trial […]
News

First Neuralink patient said to be able to control mouse through thinking

20 February 2024 | 1:55 pm
First Neuralink patient said to be able to control mouse through thinking
The first human patient implanted with a brain-chip from Neuralink appears to have fully recovered and is able to control a computer mouse using their thoughts, stated Elon Musk late on Monday. “Progress is good, and the patient seems to have made a full recovery, with no ill effects that we are aware of. Patient […]
News

NEOGAP is granted Australian patent

20 February 2024 | 1:32 pm
NEOGAP is granted Australian patent
NEOGAP Therapeutics has been granted a patent in Australia for an innovative method that opens new possibilities in the treatment and diagnosis of multiple sclerosis (MS). The patent strengthens NEOGAP’s strategic intellectual property portfolio and marks an important step in the company’s efforts to develop groundbreaking treatments for autoimmune diseases such as MS, it states. […]
News

Orion to investigate possible outsourcing of its production in Kuopio

19 February 2024 | 3:43 pm
Orion R and D
Orion Corporation is evaluating the possible outsourcing of its pharmaceutical production in Kuopio, part of its Global Operations function, to an entity outside Finland. The basis for the possible outsourcing would be the lack of competitiveness of the Kuopio plant and the high investment needs of the plant, states the company. The evaluation is due […]
News

Ultimovacs receives EMA Orphan Drug Designation

19 February 2024 | 11:19 am
Carlos de Sousa
Ultimovacs has announced that the European Medicines Agency (EMA) has issued a positive opinion on the company’s application for  Orphan Drug Designation (ODD) for its therapeutic cancer vaccine UV1 for the treatment of mesothelioma. The designation was granted based on results from the Phase II clinical trial, NIPU evaluating UV1 added to ipilimumab and nivolumab […]
News

Q&A: Jeanette Edblad

16 February 2024 | 7:24 am
Q&A: Jeanette Edblad
Jeanette Edblad is the new Director of the Office for Life Sciences at the Government Offices in Sweden. NLS asked her about her new role and about Swedish life sciences. Jeanette Edblad has been heading the unit for Entrepreneurship and Innovation, which is responsible for life science issues at the Ministry of Climate and Business. […]
News

Diamyd Medical receives FDA Fast Track designation

15 February 2024 | 8:36 am
Diamyd Medical receives FDA Fast Track designation
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Diamyd that is being investigated to improve glycemic control in recently diagnosed stage 3 Type 1 Diabetes patients with the genotype HLA DR3-DQ2. “We are very pleased with the FDA’s decision to grant Fast Track designation for Diamyd and the potential this […]